In The News

Dec 2, 2021 Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up

Nov 29, 2021 Kazia Therapeutics expands further in North America with Toronto glioblastoma study

Nov 15, 2021 Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO

Nov 10, 2021 Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled

Nov 7, 2021 Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial

Nov 4, 2021 Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy

Oct 28, 2021 Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison

Oct 14, 2021 Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison

Sep 14, 2021 Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Sep 2, 2021 Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study